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Mr. Editor
One of the important factors to reduce the spread of the human immunodeficiency virus (HIV) in Peru
is the accessibility of diagnosis through rapid tests (RP), which are applied even in the most remote
communities. However, during the five years 2011 - 2015, health establishments acquired and used more
than 10 different brands, generating confusion in applying the methodology described in the inserts and
consequently erroneous results (false positives and false negatives)(1).
To standardize the use of RP of a certain brand in health establishments nationwide, in the last five
years, the Ministry of Health commissioned the National Center for Supply of Strategic Health Resources
(CENARES) to purchase it for national distribution. The RPs that CENARES acquires previously undergo
a reactivity evaluation to observe if they comply with their diagnostic performance as reported in their
inserts(1).
The problem is that the different brands of reagents purchased by CENARES are subjected to a reactivity
evaluation only against panels of serum or plasma samples and are not evaluated against whole blood or
capillary blood; this due to the complexity of the access to reference panels. However, during the national
surveillance of HIV, RP application is mainly carried out in capillary blood, so much so that even though in
serum or plasma they report sensitivity and specificity at 100.0%, false positives and negatives continue
to be given. This leads us to deduce that it is probably because the tests carried out in the field are carried
out on blood.
Within the framework of the National HIV Surveillance, we are responsible for technically assisting the
Laboratory Network on activities related to diagnosis(1), for these reasons, it was proposed as an objective.
The grounds were to evaluate the reactivity of three different commercial brands of RP acquired by
CENARES against whole blood samples to detect antibodies against HIV.
A prospective observational study of diagnostic test evaluation was conducted during January 2020;
the approval of an ethics committee was not obtained since it was necessary to provide this technical
orientation due to the problems already mentioned.
The estimation of the sample size was designated for convenience, using a non-probabilistic sampling,
corresponding to 100 reference samples of whole blood anonymized and decoded from the Hemoteca of
the National Reference Laboratory of Sexually Transmitted Viruses HIV / AIDS of the National Institute of
Health from Peru, of which 50 were HIV positive and 50 HIV negative, with Immunoblot being the reference
test (sensitivity: 100.0%, specificity: 96.7%)(2). The three brands processed all samples: Core test HIV 1/2
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Antibody Test Kit(3), Standard Diagnostics SD Bioline
HIV-1/2 3.0(4), and CTK Biotech OnSite HIV combo
rapid test(5), being the immunochromatographic
tests carried out according to the manufacturer's
instructions (insert). Finally, the diagnostic precision
parameters were estimated using the Epidat v3.1
program and Excel.
Among the findings, we show that the three
brands evaluated had concordant specificity results
(100.0%); Likewise, we highlight that the sensitivity
of OnSite (100.0%) was superior to Core test and SD
Bioline (98.0% 95% CI 93.1-100.0). It was also found
that the Youden index obtained for the three brands
was higher than 0.97, which confirms the fact that
the possibility of having false positives or negatives
is low (Table 1).
EAmong other findings, it was found that OnSite did
not obtain false negatives or positives, while Core
test and SD Bioline did present a false negative. Since
RPs is a screening test, the ideal would be for them
to have the maximum sensitivity (100.0%) to avoid
false negatives and thus avoid infected subjects
transmitting HIV(1).
Our sensitivity results for OnSite (100.0%) agree with
Miranda et al.(6). However, they differ for SD Bioline
(98.0% versus 100.0%)(6). Likewise, when comparing
with those reported in their inserts(3-5), we can
refer that the sensitivity of OnSite was concordant
(100.0%); however, SD Bioline and Core test showed
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some difference (98.0% versus 100.0% for both
brands).
The difference shown could be because we evaluated
the RP against whole blood, while the inserts and
those of Miranda et al. were against serum and
plasma(3-6). It should be said that in general, the results
of the parameters of reactivity differ according to the
type of biological sample; Another difference could
also be because the OnSite brand strip contains the
following recombinant antigens: HIV-1 p24, gp41,
HIV-1 gp120, and HIV-2 gp36, while the SD Bioline
and Core test contain the same antigens, but not
includes gp120(3-5).
The sensitivity and specificity results obtained in the
present study represent more of our reality since
we use whole blood to evaluate simultaneously
that health facilities use mostly capillary blood. A
limitation of the study was the non-inclusion of
interfering samples due to their unavailability.
The three brands evaluated obtained a validity
index greater than or equal to 99.0% (Table 1),
which qualifies them as tests of good diagnostic
performance; Likewise, knowing that the World
Health Organization considers a sensitivity and
specificity greater than or equal to 99.0%(1), we
conclude that In this study, the CTK Biotech OnSite
HIV ½ rapid test was the kit that demonstrated the
best diagnostic performance, complying with the
ideal characteristic of a screening test.

Table 1. Reactivity results of the three rapid test brands evaluated against whole blood samples to detect
antibodies against HIV.
Core test HIV 1/2
Parameter

SD Bioline HIV 1-2 3.0

OnSite Hiv 1/2

Value

(IC 95%)

Value

(IC 95%)

Value

(IC 95%)

Sensitivity (%)

98.0

(93.1-100.0)

98.0

(93.1-100.0)

100.0

(99.0-100.0)

Specificity (%)

100.0

(99.0-100.0)

100.0

(99.0-100.0)

100.0

(99.0-100.0)

Validity index (%)

99.0

(96.6-100.0)

99.0

(96.6-100.0)

100.0

(99.5-100.0)

Positive predictive value (%)

100.0

(99.0-100.0)

100.0

(99.0-100.0)

100.0

(99.0-100.0)

Negative predictive value (%)

98.0

(93.3-100.0)

98.0

(93.3-100.0)

100.0

(99.0-100.0)

Youden index

0.98

(0.94-1.00)

0.98

(0.94-1.00)

1.00

1.00-1.00)

CI: Confidence interval 95%

https://inicib.urp.edu.pe/rfmh/vol21/iss3/29
Pág. 678
DOI: https://doi.org/10.25176/RFMH.v21i3.3941

2

Briceño-Espinoza et al.: Evaluation of three brands of rapid tests against blood
samples f
Evaluation of three brands of rapid tests

Rev. Fac. Med. Hum. 2021;21(3):677-679.

Authorship contributions: The authors participated
in the conception and design of the study; collection,
analysis and interpretation of the results; writing,
critical review and approval of the final version of the
letter.
Financing: The study was carried out within the
framework of the regular activities of the National
Institute of Health (national surveillance of HIV). The

diagnostic kits for the three rapid test brands were
provided by CENARES / MINSA.

Interest conflict: The authors declare that they have
no conflict of interest.
Received: May 31, 2021
Approved: June 14, 2021

Correspondence: Eduardo Miranda Ulloa.
Address: Defensores del Morro 2268, Chorrillos, Perú.
Telephone: (+51) 977783088
Email: fernandoul@hotmail.com

1. Norma técnica de salud de atención integral del adulto con
infección por el Virus de la Inmunodeficiencia Humana (VIH). NTS
N° 169- MINSA/2020/DGIESP (Resolución Ministerial N°:1024-2020/
MINSA) Ministerio de Salud, Perú, 2020. [Citado el 30 de mayo de
2021]. Disponible en: https://cdn.www.gob.pe/uploads/document/
file/1482085/Resoluci%C3%B3n%20Ministerial%20N%C2%B010242020-MINSA.PDF
2. Fujirebio. INNO-LIA™* HIV I/II Score [Internet]. Fujirebio: Bélgica; 2017
[Citado el 30 de mayo de 2021]. Disponible en: http://www.peramed.
com/peramed/docs/80540_EN.pdf
3. Core test HIV 1/2 Antibody Test Kit. [Internet]. Core Tecnology:
China [Citado el 30 de mayo de 2021]. Disponible en: https://www.
alibaba.com/product-detail/Blood-Analysis-System-One-StepRapid_62282551202.html

4. Standar Diagnostics SD HIV-1/2 3.0. [Internet]. República de Korea:
Abbott; 2018 [Citado el 30 de mayo de 2021]. Disponible en: https://
www.alere.com/en/home/product-details/sd-bioline-hiv-1-2-3-0.
html
5. CTK Biotech OnSite HIV Ab/Ag 4TH combo rapid test. [Internet].
San Diego, USA: CTK Biotech; 2017 [Citado el 30 de mayo de 2021].
Disponible en: https://ctkbiotech.com/product/hiv-1-2-ab-pluscombo-rapid-test/#demoTab2
6. Miranda-Ulloa E, Romero-Ruiz S, Briceño-Espinoza R, SantosAnaya D. Evaluación de tres marcas comerciales de pruebas
rápidas para la detección de VIH. Rev. Perú. med. exp. salud pública
[Internet]. 2015 Abr [Citado el 30 de mayo de 2021]; 32(2): 404-405.
Disponible
en:
http://www.scielo.org.pe/scielo.php?script=sci_
arttext&pid=S1726-46342015000200036

Indexed in:

LETTERS TO THE EDITOR

BIBLIOGRAPHIC REFERENCES




INSTITUTO DE
INVESTIGACIÓNES EN
CIENCIAS BIOMÉDICAS

https://alicia.concytec.gob.pe/vufind/
Vol.21 N°3
Julio-Setiembre 2021

Published by INICIB-URP, 2021

Pág. 679

3

